Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

Acute Myeloid Leukemia (AML) Market Report Overview

The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the AML therapeutics market.

AML Market Outlook 2022-2032 ($ Billion)

Buy the Full Report to Know More About the AML Market Forecast

Download a Free Sample Report

Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients.

AML Market Dynamics

• The sales of two menin inhibitors, revumenib and ziftomenib, represent the most high-profile driver as highlighted by KOLs, totaling $393 million in 2032. Targeting a new segment of difficult-to-treat patients, both inhibitors are anticipated to be launched in the US and 5EU.
• Pipeline agents to be used as therapies for improving HSCT outcomes are important market drivers as they create a brand-new market segment as HSCT aids. Orca-T is heading towards the US and 5EU, while mocravimod targets the US, 5EU, and Japan.
• The anticipated launch of iodine-131-apamistamab in the markets of the US and 5EU contributes to the robust growth of the AML market, thanks to its potentially higher price tag as a radiopharmaceutical, and its robustness in clearing blasts in a wider population of patients for conducting effective HSCT.
• Several late-stage pipeline drugs with novel MOAs have received orphan drug designation from the FDA. As such, they are granted a potential seven years of market exclusivity after approval.

Buy the full Report for Additional Insights on the Key AML Market Dynamics, Download a Free Sample Report

AML Market Segmentation by Country

The key countries in the AML market are the United States, France, Germany, Italy, Spain, the UK, Japan, and Urban China. In 2022, the US dominated the total AML market in the 8MM occupying over 60% of the market share. The dominance of the US within the 8MM is due to higher drug prices and the market entries of a greater range of novel therapies.

AML Market Analysis by Country, 2022 (%)

Buy the Full Report for Country-Wise Insights on the AML Market, Download a Free Sample Report

AML Market Segmentation by Drug Classes

The key drugs in the AML market are targeted therapies – small molecule, cell therapies, targeted therapies – biologics, branded chemotherapy, hypomethylating agents, and generic chemotherapy. In 2022, small molecule drugs in the class of targeted therapy contributed the highest AML market sales.

AML Market Analysis by Drug Classes, 2022 (%)

Buy the Full Report for Drug-Class Insights on the AML Market, Download a Free Sample Report

AML Market Segmentation by Sponsors

The key sponsors conducting Phase I to III clinical trials in the AML market are CSPC Pharmaceutical Group, Astex Pharmaceuticals Inc, Zhejiang University, Novartis AG, Daiichi Sankyo Co Ltd, Celgene Corp, AbbVie Inc, Dana-Farber Cancer Institute Inc, and Bristol Myers Squibb Co among others. As of September 2023, CSPC Pharmaceutical Group from China has been the most active sponsor of clinical trials in AML. The company is developing the FLT3 inhibitor SKLB-1028, gearing towards the R/R setting in the domestic market.

AML Market Analysis by Sponsors, 2023 (%)

Buy the Full Report for Sponsor-Wise Insights on the AML Market, Download a Free Sample Report

Segments Covered in this Report

AML Country Outlook ($ Billion, 2022-2032)

• The US
• UK
• Germany
• France
• Italy
• Spain
• Japan
• Urban China

AML Drugs Outlook (%, 2022-2032)

• Targeted Therapies – Small Molecule
• Cell Therapies
• Targeted Therapies – Biologics
• Branded Chemotherapy
• Hypomethylating Agents
• Generic Chemotherapy

Scope

• Annualized AML therapeutics market revenue in 8MM (the US, Germany, and the UK), the annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032 covering three-time points: base year, 5-year, and 10-year.
• Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for AML treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 8MM AML therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model

Forecast includes 8 countries

Forecast covers 2022-2032

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the AML therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the AML therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.